Robert Bucki Selected Research

Actins (F Actin)

1/2018	Targeting polyelectrolyte networks in purulent body fluids to modulate bactericidal properties of some antibiotics.
6/2015	Polyelectrolyte-mediated increase of biofilm mass formation.
12/2011	Cathelicidin LL-37 increases lung epithelial cell stiffness, decreases transepithelial permeability, and prevents epithelial invasion by Pseudomonas aeruginosa.
2/2010	Cathelicidin LL-37: a multitask antimicrobial peptide.
9/2007	Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum.
10/2005	Anionic poly(amino acid)s dissolve F-actin and DNA bundles, enhance DNase activity, and reduce the viscosity of cystic fibrosis sputum.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert Bucki Research Topics

Disease

29	Infections 07/2022 - 06/2003
18	Neoplasms (Cancer) 07/2022 - 01/2014
18	Inflammation (Inflammations) 07/2022 - 09/2007
6	Cystic Fibrosis (Mucoviscidosis) 01/2022 - 06/2003
5	Sepsis (Septicemia) 04/2020 - 12/2008
5	Bacterial Infections (Bacterial Infection) 02/2019 - 02/2010
4	Multiple Sclerosis 01/2019 - 06/2010
3	Colonic Neoplasms (Colon Cancer) 01/2020 - 01/2015
3	Endotoxemia 02/2019 - 06/2006
3	Tick-Borne Encephalitis (Encephalitis, Tick Borne) 08/2018 - 01/2011
2	COVID-19 01/2022 - 03/2021
2	Breast Neoplasms (Breast Cancer) 01/2022 - 04/2018
2	Ovarian Neoplasms (Ovarian Cancer) 10/2021 - 01/2021
2	Mycoses (Diseases, Fungus) 12/2020 - 01/2016
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2019 - 12/2017
2	Neurodegenerative Diseases (Neurodegenerative Disease) 08/2018 - 06/2010
2	Carcinogenesis 04/2018 - 02/2016
2	Wounds and Injuries (Trauma) 06/2011 - 12/2008
2	Meningitis 01/2011 - 12/2010
1	Urinary Bladder Neoplasms (Bladder Cancer) 07/2022
1	Pancreatitis 01/2022
1	Otitis Media 12/2021
1	Leukoplakia 07/2021
1	Hemolysis 01/2021
1	Ovarian Epithelial Carcinoma 01/2021
1	Cross Infection (Nosocomial Infection) 01/2021
1	Tracheoesophageal Fistula 09/2020
1	Laryngeal Neoplasms (Laryngeal Cancer) 09/2020
1	Multiple Myeloma 11/2019
1	Weight Loss (Weight Reduction) 11/2019
1	Xerostomia 06/2019
1	Urinary Tract Infections (Urinary Tract Infection) 05/2019
1	Gaucher Disease (Gaucher's Disease) 02/2019
1	Hematologic Neoplasms (Hematological Malignancy) 02/2019

Drug/Important Bio-Agent (IBA)

11	Anti-Bacterial Agents (Antibiotics)IBA 06/2022 - 09/2007
11	GelsolinIBA 01/2022 - 12/2008
10	CathelicidinsIBA 07/2022 - 02/2010
10	cerageninsIBA 05/2022 - 01/2016
8	Peptides (Polypeptides)IBA 05/2022 - 06/2003
7	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 07/2022 - 06/2010
6	GoldIBA 01/2022 - 02/2019
6	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 10/2005
6	Actins (F Actin)IBA 01/2018 - 10/2005
5	Pharmaceutical PreparationsIBA 12/2020 - 11/2010
5	Proteins (Proteins, Gene)FDA Link 06/2019 - 11/2010
5	LipopolysaccharidesIBA 06/2010 - 07/2005
4	Antineoplastic Agents (Antineoplastics)IBA 10/2021 - 05/2016
4	CollagenIBA 07/2021 - 07/2014
4	ceragenin CSA-13IBA 04/2018 - 09/2007
3	EnzymesIBA 07/2022 - 08/2018
3	LigandsIBA 01/2022 - 02/2016
3	VimentinIBA 01/2022 - 06/2015
3	Indicators and Reagents (Reagents)IBA 04/2020 - 09/2010
3	SphingolipidsIBA 02/2019 - 03/2017
3	Antimicrobial PeptidesIBA 04/2018 - 06/2003
3	Deoxyribonucleases (DNase)FDA Link 01/2018 - 10/2005
3	LipidsIBA 03/2013 - 06/2010
2	SphingosineIBA 07/2022 - 12/2017
2	AntibodiesIBA 01/2022 - 03/2021
2	SARS-CoV-2 spike proteinIBA 01/2022 - 03/2021
2	ceragenin CSA-131IBA 10/2021 - 01/2020
2	Biological ProductsIBA 10/2020 - 02/2010
2	ferric oxide (iron oxide)IBA 01/2020 - 02/2019
2	Phosphatidylinositols (Phosphatidylinositol)IBA 07/2019 - 02/2019
2	CeramidesIBA 02/2019 - 12/2017
2	Vitamin D-Binding ProteinIBA 08/2018 - 01/2011
2	Interleukin-8 (Interleukin 8)IBA 10/2017 - 06/2010
2	IntegrinsIBA 10/2017 - 01/2014
2	CytokinesIBA 10/2017 - 01/2013
2	Interleukin-6 (Interleukin 6)IBA 11/2014 - 06/2010
2	Peptide Hydrolases (Proteases)FDA Link 03/2013 - 01/2013
2	Thrombin FDA Link 01/2013 - 06/2006
2	Clarithromycin (Biaxin)FDA LinkGeneric 09/2009 - 02/2007
1	sphingosine kinaseIBA 07/2022
1	Virulence Factors (Pathogenicity Factors)IBA 06/2022
1	Metformin (Glucophage)FDA LinkGeneric 01/2022
1	resazurinIBA 01/2022
1	Cysteine (L-Cysteine)FDA Link 01/2022
1	Proline Oxidase (Proline Dehydrogenase)IBA 01/2022
1	Adenylate KinaseIBA 01/2022
1	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2021
1	Immune Checkpoint InhibitorsIBA 01/2021
1	LactamsIBA 01/2021
1	SiliconesIBA 09/2020
1	Deoxyglucose (2 Deoxy D glucose)IBA 04/2020
1	Antimicrobial Cationic PeptidesIBA 12/2019
1	Sphingomyelin Phosphodiesterase (Sphingomyelinase)IBA 11/2019
1	AcidsIBA 11/2019
1	PolymersIBA 11/2019
1	Artificial SalivaIBA 06/2019
1	Immunoglobulins (Immunoglobulin)IBA 06/2019
1	SolutionsIBA 05/2019
1	Blood Proteins (Serum Proteins)IBA 02/2019
1	Fingolimod Hydrochloride (FTY720)FDA Link 01/2019

Therapy/Procedure

9	Therapeutics 01/2021 - 01/2009
1	Antibiotic Prophylaxis 06/2022
1	Immunotherapy 01/2021
1	Drug Therapy (Chemotherapy) 01/2021
1	Laryngectomy 09/2020
1	Artificial Larynx (Voice Prosthesis) 09/2020